{
    "Case ID": "006506",
    "Crime_Name": [
        "Trademark Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Trademark Registration Opposition"
    ],
    "Legal_Issue": [
        "Whether AstraZeneca's proposed trademarks (color and shape of tablets) are distinctive enough to be registered"
    ],
    "Governing_Law": [
        "Trade-marks Act"
    ],
    "Procedural_Stage": [
        "Appeal at Federal Court and Court of Appeal, remanded to Trial Division"
    ],
    "Evidence_Assessment": [
        "Many red-brown pills existed in the market; pharmacists identified tablets by Drug Identification Number, not color or shape"
    ],
    "Decision_Outcome": [
        "Trademark applications denied"
    ],
    "Burden_of_Proof": [
        "On applicant (AstraZeneca) to prove distinctiveness"
    ],
    "Credibility_Factor": [
        "Lack of evidence showing consumer association of color/shape with source"
    ],
    "Legal_Rule": [
        "A trademark is 'distinctive' if it actually distinguishes the product or is inherently distinctive; color alone is not inherently distinctive without proof"
    ],
    "Standard_of_Review": [
        "Statutory interpretation and factual assessment under Trade-marks Act"
    ],
    "Procedural_Issue": [
        "Remand for further review based on new evidence"
    ],
    "Grounds_for_Claim": [
        "Lack of distinctiveness in color and shape of felodipine tablets"
    ],
    "Outcome_on_Merits": [
        "AstraZeneca failed to prove inherent or acquired distinctiveness"
    ],
    "Decision_Maker": [
        "Federal Court, Court of Appeal, Trial Division"
    ],
    "Judicial_Review_Outcome": [
        "Appeals allowed, applications denied"
    ],
    "Review_Standard": [
        "Correctness and reasonableness depending on legal and factual issues"
    ],
    "Procedural_Fairness_Assessment": [
        "Case remanded for fair consideration of new evidence"
    ],
    "Key_Evidence_Considered": [
        "Market presence of similar colored pills, pharmacist identification practices, consumer perception data"
    ],
    "Legal_Framework": [
        "Canadian trademark law under Trade-marks Act"
    ],
    "Applicant_Challenge": [
        "AstraZeneca's inability to demonstrate distinctiveness"
    ],
    "Court_Result": [
        "Denial of trademark registration"
    ],
    "Legal_Rule_Source": [
        "Trade-marks Act"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Novopharm opposed registration on grounds of non-distinctiveness"
    ],
    "Evidence_Type": [
        "Market survey data, expert testimony, comparative product analysis"
    ],
    "Remedy_Requested": [
        "Opposition to trademark registration"
    ],
    "Outcome": [
        "Trademark applications refused, Novopharm awarded costs"
    ],
    "Decision_Authority": [
        "Trial Division of the Federal Court (after remand)"
    ],
    "Remedy_Sought": [
        "Prevention of registration of non-distinctive marks"
    ],
    "Resolution_Mechanism": [
        "Judicial review and opposition proceedings"
    ],
    "Legal_Provision": [
        "Section related to distinctiveness under Trade-marks Act"
    ],
    "Authority": [
        "Federal Court of Canada"
    ],
    "Claimant_Status": [
        "AstraZeneca as applicant, Novopharm as opponent"
    ],
    "Legal_Provision_Cited": [
        "Provisions regarding distinctiveness in trademark registration"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Marks not inherently distinctive and no acquired distinctiveness proven"
    ],
    "Applicable_Process": [
        "Trademark opposition and appeal process"
    ],
    "Outcome_of_Review": [
        "Appeal allowed, application denied"
    ],
    "Pending_Relief_or_Application": [
        "Trademark registration applications withdrawn or denied"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Trade-marks Act â€“ distinctiveness requirement"
    ]
}